Drug intelligence / Profile preview

mSCF CAR

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

mSCF CAR is a ligand-based Chimeric Antigen Receptor (CAR) designed to target c-kit (CD117) using its cognate ligand, stem cell factor (SCF). This CAR is utilized to modify gamma delta (γδ) T cells, enabling them to recognize and kill c-kit-expressing malignant cells. It is being investigated as a potential allogeneic, off-the-shelf therapeutic strategy for acute myeloid leukemia (AML), a condition where high c-kit expression is associated with chemotherapy resistance and poor prognosis. Preclinical studies have demonstrated its efficacy in vitro against c-kit+ AML cell lines.

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on mSCF CAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mSCF CAR.

Explore the full profile